Navigation Links
FDA Formally Accepts Dune Medical's MarginProbe™ System Pre-Market Approval (PMA) Application and Grants Expedited Review Status
Date:5/16/2011

FRAMINGHAM, Mass., May 16, 2011 /PRNewswire/ -- Dune Medical Devices, Inc. today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) application for the MarginProbe™ System.  The FDA's actions mean that the PMA application was sufficiently complete and ready for substantive review.  Additionally, the FDA believes MarginProbe represents a breakthrough technology that may offer a clinically meaningful advantage, and, since there is no legally marketed alternative device, confirmed that the PMA application has been granted expedited review.

"We're extremely pleased that the FDA has accepted the MarginProbe System PMA application and granted expedited review," said Dune Medical CEO Bill Densel.  "Our mission is to develop a range of applications that allow physicians to detect cancer in targeted tissue in real time, and react immediately.  This milestone with MarginProbe brings us one step closer to providing surgeons with an intraoperative technology that detects microscopically positive margins in patients undergoing surgery for breast cancer."

The PMA submission includes data from the pivotal study recently presented Friday, April 29 at the 12th Annual Meeting of the American Society of Breast Surgeons (ASBS) in Washington, DC.

Successful breast conserving surgery requires cancer-free margins at the edges of excised tissue.  However, real time, intraoperative methods currently available to surgeons are limited in their ability to identify microscopically-positive margins.  Because of this, patients frequently require re-excision procedures, which are reported to take place in up to 30 percent of patients.  Readmissions for re-excision to obtain clear margins have been shown to increase cost and emotional distress for patients, as well as have the potential for more scarring and deformation at the surgical site.  

About the MarginProbe™ System

The MarginProbe System provides real time, intraoperative detection of cancerous tissue at the edges of excised breast tissue, thereby enabling surgeons to immediately resect additional tissues.  In clinical studies as an adjunct to standard of care, it has been shown to improve a surgeon's ability to achieve a complete resection of the disease, leading to lower rates of re-excision procedures.  The MarginProbe System is commercially available in Europe.  It is an investigational device in the United States.

About Dune Medical Devices

Dune Medical Devices is a private medical device company developing applications for the real time detection of cancerous tissues during surgical, interventional, and diagnostic procedures.  As a stand-alone platform or in combination with imaging modalities, Dune's breakthrough technology will provide physicians with information that has the potential to improve procedure success rates, better outcomes, and lower costs. Founded in 2002 by Dr. Dan Hashimshony and financed by Apax Partners, the Company has offices in the U.S., Europe, and Israel.  For more information, please visit www.dunemedical.com.


'/>"/>
SOURCE Dune Medical Devices, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaNet and Anapharm Europe Formally End Joint Venture
2. Paul Meade Accepts Invitation to Speak at AACE Annual Meeting
3. FDA Accepts Investigational New Drug Application for ARI-3030MO; First in Man Clinical Trial to Begin During First Quarter of 2011
4. NYSE Amex Accepts China Shenghuos Compliance Plan for Continued Listing
5. The European Medicines Agency Validates and Accepts Cell Therapeutics Marketing Authorization Application for Pixuvri™
6. The SCOOTER Store Accepts Medicare Contracts
7. FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA for Review
8. FDA Accepts Sanofi Pasteur File Submission for Novel Influenza Vaccine Delivered by Intradermal Microinjection
9. FDA Accepts Sanofi Pasteurs Application to Expand Indication of Menactra® Vaccine to Infants and Toddlers
10. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
11. FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/7/2017)... 6, 2017   Provista, a proven leader ... billion in purchasing power, today announced a new resource ... The Newsroom is the online home for case ... expert bios, news releases, slideshows and events. ... wealth of resources at their fingertips, viewers can also ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
Breaking Medicine News(10 mins):